Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-week randomized double-blind placebo-controlled Phase IIa trial of AZD5069 in COPD
2010-021217-23Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD5069 with Placebo (2 arms). Primary endpoint: Safety and tolerability of AZD5069. Started Jul 2010; status: completed.
02
Drugs
azd5069
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-021217-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021217-23.